ストックスクリーナーアプリを入手
8.485
13.51%
-1.325
前日終値:
$9.81
開ける：
$9.88
24時間の取引高:
1.99M
Relative Volume:
1.79
時価総額：
$515.85M
収益：
-
当期純損益:
$-156.40M
株価収益率:
-2.587
EPS:
-3.2799
ネットキャッシュフロー:
$-151.53M
1週間 パフォーマンス:
-4.56%
1か月 パフォーマンス:
+10.77%
6か月 パフォーマンス:
+1.98%
1年 パフォーマンス:
+137.68%
1日の値動き範囲:
$8.31
$9.90
1週間の範囲:
$8.31
$10.29
52週間の値動き範囲:
$2.80
$13.67
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
名前
Kyverna Therapeutics Inc
セクター
電話
(510) 626-8331
住所
5980 HORTON STREET, EMERYVILLE
Compare KYTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
8.485 | 515.85M | 0 | -156.40M | -151.53M | -3.2799 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-20 | 開始されました | William Blair | Outperform |
| 2025-05-27 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2024-10-10 | 開始されました | UBS | Buy |
| 2024-10-09 | 開始されました | Rodman & Renshaw | Buy |
| 2024-07-03 | 開始されました | H.C. Wainwright | Neutral |
| 2024-03-04 | 開始されました | JP Morgan | Overweight |
| 2024-03-04 | 開始されました | Leerink Partners | Outperform |
| 2024-03-04 | 開始されました | Morgan Stanley | Overweight |
| 2024-03-04 | 開始されました | Wells Fargo | Overweight |
すべてを表示
Kyverna Therapeutics Inc (KYTX) 最新ニュース
Cartesian Therapeutics Inc. : RNAC - 24/7 Wall St.
Kyverna Therapeutics (NASDAQ:KYTX) Shares Down 11.1%Time to Sell? - MarketBeat
Enterprise value to EBIT forward of Kyverna Therapeutics, Inc. – NASDAQ:KYTX - TradingView
Price to sales forward of Kyverna Therapeutics, Inc. – NASDAQ:KYTX - TradingView
Price to book forward of Kyverna Therapeutics, Inc. – NASDAQ:KYTX - TradingView
Kyverna Therapeutics (KYTX) Jefferies London Healthcare Conference 2025 Summary - Quartr
Kyverna Therapeutics’ (KYTX) Insights into Stiff Person Syndrome and Beyond - Insider Monkey
Kyverna Therapeutics, Inc. Files 8-K: Key Details on Nasdaq Listing, Emerging Growth Status, and Executive Signatures - Minichart
Kyverna Therapeutics Amends Term Loan, Extends Capital Access - TipRanks
Kyverna Therapeutics (KYTX) extends access to $150M term loan tranches - Stock Titan
Kyverna Therapeutics, Inc. $KYTX Shares Bought by AIGH Capital Management LLC - MarketBeat
Nine biopharma companies name legal officers - BioXconomy
Kyverna Therapeutics: The Autoimmune CAR T Beachhead Is Bigger Than SPS (KYTX) - Seeking Alpha
KYTX Stock Soars After Hours: What’s Driving The Rally? - Stocktwits
KYTXKyverna Therapeutics Inc Dividends - Finviz
Kyverna Therapeutics, Inc.(NasdaqGS: KYTX) added to Russell 2000 Index - marketscreener.com
Kyverna Therapeutics, Inc.(NasdaqGS: KYTX) added to Russell 2500 Growth Benchmark - marketscreener.com
Kyverna Therapeutics, Inc.(NasdaqGS: KYTX) added to Russell 2000 Value Benchmark - marketscreener.com
Kyverna Therapeutics, Inc.(NasdaqGS:KYTX) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Kyverna Therapeutics, Inc.(NasdaqGS: KYTX) added to Russell 2000 Growth Benchmark - marketscreener.com
Kyverna Therapeutics, Inc.(NasdaqGS: KYTX) added to Russell 3000E Growth Benchmark - marketscreener.com
Kyverna Therapeutics, Inc.(NasdaqGS: KYTX) added to Russell 3000E Index - marketscreener.com
Kyverna Therapeutics, Inc.(NasdaqGS: KYTX) added to Russell 3000E Value Benchmark - marketscreener.com
Cabaletta Bio: The Market Sold The EULAR News, I'm Buying (NASDAQ:CABA) - Seeking Alpha
Kyverna Therapeutics, Inc. Actuals & Estimates (NASDAQ:KYTX) - TradingView
KYTX Forecast — Price Target — Prediction for 2027 - TradingView
Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition - The Manila Times
Kyverna Therapeutics Appoints Ritesh Srivastava as Chief - GlobeNewswire
Press Release: Kyverna Therapeutics Names Greg Martini as Chief Financial Officer - Moomoo
KYTX News | KYVERNA THERAPEUTICS INC (NASDAQ:KYTX) - ChartMill
KYVERNA THERAPEUTICS INC (KYTX) Stock Chart - ChartMill
Kyverna Therapeutics Inc (KYTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kyverna Therapeutics Inc (KYTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Kyverna Therapeutics Inc (KYTX) Institutional Confidence - TradingKey
Kyverna Therapeutics Inc (KYTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Kyverna Therapeutics Inc (KYTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kyverna Therapeutics Inc (KYTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
KYVERNA THERAPEUTICS INC (KYTX) Stock Price & Overview - ChartMill
Kyverna Therapeutics Inc (KYTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Kyverna Therapeutics Inc (KYTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Kyverna Therapeutics Inc (KYTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Kyverna Therapeutics (KYTX) Posts Modest Gain Amid Biotech Market StabilizationOBV Trend Line - dars.gov.et
Kyverna Therapeutics to Participate in Upcoming September Invest - GuruFocus
Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight - GlobeNewswire Inc.
Kyverna Therapeutics (KYTX) Rises 1.62% as Stock Tests Key ResistanceTick Index - dars.gov.et
Kyverna vs. Vertex: Clinical-Stage Risk vs. Cash-Flow Stability in Biotech InvestingNews and Statistics - IndexBox
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026? - The Motley Fool
Kyverna Therapeutics, Inc. (KYTX) Presents at Jefferies Global Healthcare Conference 2026Slideshow - Seeking Alpha
H.C. Wainwright reiterates Kyverna stock rating on autoimmune data - Investing.com UK
H.C. Wainwright reiterates Kyverna stock rating on autoimmune data By Investing.com - Investing.com Nigeria
Advancing CAR T for Drug-Free Remission in Autoimmune Disease with Kyverna Therapeutics' Dr Naji Gehchan - Bioprocess Online
Kyverna Therapeutics Inc (KYTX) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):